COST EFFECTIVENESS OF ZOLEDRONIC ACID VS. PAMIDRONATE OR NO THERAPY FOR THE TREATMENT OF BONE METASTASES SECONDARY TO PROSTATE CANCER

被引：0
|
作者：
Carter, J. A. [1 ]
Bains, M. [2 ]
Chandiwana, D. [2 ]
Kaura, S. [3 ]
Botteman, M. F. [1 ]
机构：
[1] Pharmerit N Amer LLC, Bethesda, MD USA
[2] Novartis Pharmaceut UK Ltd, Camberley, Surrey, England
[3] Novartis Pharmaceut, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1174
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A447 / A447
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of oral ibandronic acid versus i.v. zoledronic acid and i.v. pamidronate in the treatment of metastatic bone disease in breast cancer
    De Cock, Erwin
    Hutton, John
    Canney, Peter
    Body, Jean-Jacques
    Neary, Maureen
    Lewis, Gavin
    ANNALS OF ONCOLOGY, 2004, 15 : 50 - 50
  • [32] Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
    Rosen, LS
    Gordon, DH
    Dugan, W
    Major, P
    Eisenberg, PD
    Provencher, L
    Kaminski, M
    Simeone, J
    Seaman, J
    Chen, BL
    Coleman, RE
    CANCER, 2004, 100 (01) : 36 - 43
  • [33] Combined chemotherapy of zoledronic acid and pamidronate in the treatment of bone metastases from nonsmall cell lung cancer and the effects on pain stress and bone metabolic indices
    Huang, Kun
    Tang, Xiao
    Tang, Fang
    DRUG DEVELOPMENT RESEARCH, 2024, 85 (01)
  • [34] Efficacy of zoledronic acid in the prevention of bone metastases in patients with locally advanced prostate cancer
    Musaev, T. N.
    Zeinalov, B. S.
    Kerimov, A. Kh.
    Guliev, F. A.
    Musaev, I. N.
    Alizade, A. M.
    Adzhalov, O. V.
    ONKOUROLOGIYA, 2011, 7 (01): : 62 - 65
  • [35] Zoledronic acid compliance and persistency in bone metastases due to breast, lung, and prostate cancer
    Feinberg, B. A.
    Gilmore, J. W.
    Saleh, M. N.
    Gondesen, T.
    Jackson, J.
    Barghout, V.
    Mody-Patel, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Zoledronic acid effective as treatment for bone complications in prostate cancer patients
    不详
    ONCOLOGY-NEW YORK, 2002, 16 (09): : 1202 - 1202
  • [37] Zoledronic acid for the treatment of prostate cancer
    Finianos, Antoine
    Aragon-Ching, Jeanny B.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (06) : 657 - 666
  • [38] Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer
    Hess, Gregory
    Barlev, Arie
    Chung, Karen
    Hill, Jerrold W.
    Fonseca, Eileen
    RADIATION ONCOLOGY, 2012, 7
  • [39] Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer
    Gregory Hess
    Arie Barlev
    Karen Chung
    Jerrold W Hill
    Eileen Fonseca
    Radiation Oncology, 7
  • [40] A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN COUNTRIES
    Botteman, M.
    Carter, J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
12345